BioDelivery Sciences Expands Upon Report from Pain Management Task Force
June 24, 2019 08:00 ET
|
BioDelivery Sciences International, Inc.
Company’s Activities Support Buprenorphine Recommendations Including: Primary Use of Buprenorphine in Chronic Pain when Clinically IndicatedHaving Payers Provide Coverage and Reimbursement for...
BioDelivery Sciences Announces Upcoming Investor Conference Presentations
May 29, 2019 16:10 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., May 29, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Strengthens Financial Position with Debt Refinancing
May 28, 2019 16:10 ET
|
BioDelivery Sciences International, Inc.
New Agreement is Cash Flow Accretive, Lowers Cost of Capital and Extends Debt Maturity Reduces Annual Interest Costs by Approximately $1.5 million Increases Flexibility to Continue Growth Trajectory...
BioDelivery Sciences Reports Strong First Quarter 2019 Results and Raises BELBUCA® Full-Year Expectations
May 06, 2019 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® Net Sales Increased by 134% versus Prior Year to All-time High of $18.7 MillionSymproic® Acquisition and Commercial Integration Successfully CompletedCompany Raises Full-Year BELBUCA Net...
BioDelivery Sciences to Report Fourth Quarter and Full Year 2018 Financial Results
February 21, 2019 07:45 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 21, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...
BioDelivery Announces Expanded Preferred Insurance Coverage For BELBUCA®
February 04, 2019 08:03 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Feb. 04, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Appoints Terry Coelho as Chief Financial Officer
January 15, 2019 07:30 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Jan. 15, 2019 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients...
BioDelivery Sciences Reports Strong Third Quarter 2018 Financial Results
November 08, 2018 16:05 ET
|
BioDelivery Sciences International, Inc.
BELBUCA® continued on an accelerated growth trajectory, with revenue increasing 92% YOY and 27% versus prior quarterBELBUCA total prescriptions experienced its largest quarter over quarter increase...
BioDelivery Sciences Announces Further Significant Expanded Preferred Coverage For BELBUCA®
November 01, 2018 16:10 ET
|
BioDelivery Sciences International, Inc.
More than 100 million Covered Lives Now Have Preferred Access to BELBUCA RALEIGH, N.C., Nov. 01, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly...
BioDelivery Sciences to Present at the Cantor Fitzgerald Global Healthcare Conference and the Ladenburg Thalmann 2018 Healthcare Conference
September 25, 2018 08:00 ET
|
BioDelivery Sciences International, Inc.
RALEIGH, N.C., Sept. 25, 2018 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a rapidly growing commercial stage specialty pharmaceutical company dedicated to patients...